1
|
Cooper SE, Zhang S, Haines D, Mayer KH, Amico KR, Landovitz RJ, Hendrix CW, Marzinke MA, Chege W, McCauley M, Gulick RM. Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial. AIDS Behav 2024:10.1007/s10461-024-04451-7. [PMID: 39083151 DOI: 10.1007/s10461-024-04451-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/20/2024] [Indexed: 09/14/2024]
Abstract
Adherence drives efficacy in PrEP clinical trials. We compared drug concentrations and self-reported adherence in HPTN069/ACTG5305, a double-blinded, randomized trial of the safety and tolerability of candidate PrEP regimens that included maraviroc (MVC), tenofovir (TDF), and emtricitabine (FTC). Plasma drug concentrations and self-reported adherence by computer-assisted self-interview (CASI) were assessed at study weeks 24 and 48. Descriptive statistics and a generalized linear model were used to assess the association between selected demographic factors, self-report of daily medication adherence and plasma drug concentrations consistent with daily adherence. Among 718 paired observations from 370 participants, 43% (306/718) reported daily adherence by CASI, 65% (467/718) had drug concentrations consistent with daily adherence and 11% (81/718) had CASI responses that reported daily adherence despite having drug concentrations consistent with less-than-daily adherence. In adjusted analyses, participants who were assigned male at birth (aOR 1.42 [95% CI 1.02, 1.97]), older (5-year increments aOR 1.10 [95% CI 1.09, 1.11]), White (aOR 2.2 [95% CI 1.88, 2.56]), had advanced education (aOR 3.89 [95% CI 2.97, 5.09]), were employed (aOR 1.89 [95% CI 1.50, 2.40]), or partnered/married (aOR 2 [95% CI 1.72, 2.32]) were more likely to have drug concentrations consistent with daily adherence. Participants who were not employed (aOR 2.7 [95% CI 1.31, 5.55]) or who were single/not partnered (aOR 2.33 [CI 95% 1.25, 4.34]) were more likely to have drug concentrations that did not reflect daily adherence despite self-reported PrEP adherence. These findings support the need for ongoing adherence counseling in clinical trials of new PrEP regimens.
Collapse
Affiliation(s)
- Stanley E Cooper
- Division of Infectious Diseases, Weill Cornell Medicine, 525 East 68th Street, Baker 24, New York, NY, 10065, USA.
| | | | | | | | | | | | - Craig W Hendrix
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Mark A Marzinke
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | | | - Roy M Gulick
- Division of Infectious Diseases, Weill Cornell Medicine, 525 East 68th Street, Baker 24, New York, NY, 10065, USA
| |
Collapse
|
2
|
Rhodes SD, Alonzo J, Mann-Jackson L, Aviles LR, Tanner AE, Galindo CA, Bessler PA, Courtenay-Quirk C, Garcia M, Sucaldito AD, Smart BD, Goldenberg T, Reboussin BA. Preexposure Prophylaxis Uptake Among Spanish-Speaking Transgender Women: A Randomized Controlled Trial in North and South Carolina, 2019-2022. Am J Public Health 2024; 114:68-78. [PMID: 38091558 PMCID: PMC10726943 DOI: 10.2105/ajph.2023.307444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/03/2023] [Indexed: 12/18/2023]
Abstract
Objectives. To evaluate Chicas Creando Acceso a la Salud (Girls Creating Access to Health; ChiCAS), a Spanish-language, small-group intervention designed to increase preexposure prophylaxis (PrEP) use, consistent condom use, and medically supervised gender-affirming hormone therapy use among Spanish-speaking transgender Latinas who have sex with men. Methods. Participants were 144 HIV-negative Spanish-speaking transgender Latinas, aged 18 to 59 years, living in North and South Carolina. From July 2019 to July 2021, we screened, recruited, and randomized them to the 2-session ChiCAS intervention or the delayed-intervention waitlist control. Participants completed assessments at baseline and 6-month follow-up. Follow-up retention was 94.4%. Results. At follow-up, relative to control participants, ChiCAS participants reported increased PrEP use (adjusted odds ratio [AOR] = 4.64; 95% confidence interval [CI] = 1.57, 13.7; P < .006). However, ChiCAS participants did not report increased use of condoms or medically supervised gender-affirming hormone therapy. ChiCAS participants reported increases in knowledge of HIV (P < .001), sexually transmitted infections (P < .001), and gender-affirming hormone therapy (P = .01); PrEP awareness (P < .001), knowledge (P < .001), and readiness (P < .001); condom use skills (P < .001); and community attachment (P < .001). Conclusions. The ChiCAS intervention was efficacious in increasing PrEP use among Spanish-speaking, transgender Latinas in this trial. (Am J Public Health. 2024;114(1):68-78. https://doi.org/10.2105/AJPH.2023.307444).
Collapse
Affiliation(s)
- Scott D Rhodes
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Jorge Alonzo
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Lilli Mann-Jackson
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Lucero Refugio Aviles
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Amanda E Tanner
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Carla A Galindo
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Patricia A Bessler
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Cari Courtenay-Quirk
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Manuel Garcia
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Ana D Sucaldito
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Benjamin D Smart
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Tamar Goldenberg
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| | - Beth A Reboussin
- Scott D. Rhodes, Jorge Alonzo, Lilli Mann-Jackson, and Manuel Garcia are with the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC. At trial initiation, Lucero Refugio Aviles was with the Triad Health Project, Greensboro, NC; she completed the study while at the Department of Social Sciences and Health Policy, Wake Forest University School of Medicine. Amanda E. Tanner and Tamar Goldenberg are with the Department of Public Health Education, University of North Carolina, Greensboro. Carla A. Galindo, Patricia A. Bessler, and Cari Courtenay-Quirk are with the US Centers for Disease Control and Prevention, Atlanta, GA. Ana D. Sucaldito is with the Clinical and Translational Science Institute, Wake Forest University School of Medicine. Benjamin D. Smart is with the Karolinska Institutet, Stockholm, Sweden. Beth A. Reboussin is with the Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine
| |
Collapse
|
4
|
Konda KA, Torres TS, Mariño G, Ramos A, Moreira RI, Leite IC, Cunha M, Jalil EM, Hoagland B, Guanira JV, Benedetti M, Pimenta C, Vermandere H, Bautista‐Arredondo S, Vega‐Ramirez H, Veloso VG, Caceres CF, Grinsztejn B. Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study. J Int AIDS Soc 2022; 25 Suppl 5:e25974. [PMID: 36225148 PMCID: PMC9557020 DOI: 10.1002/jia2.25974] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Accepted: 07/19/2022] [Indexed: 11/06/2022] Open
Abstract
Introduction The HIV epidemic continues to disproportionately impact Latin‐American transgender women (TGW). We assessed factors associated with long‐term pre‐exposure prophylaxis (PrEP) engagement and adherence among TGW enrolled in the Implementation of PrEP (ImPrEP) study, the largest PrEP demonstration study in Latin America. Methods HIV‐negative TGW aged ≥18 years reporting 1+eligibility criteria in the 6 months prior to enrolment (e.g. sex partner known to be living with HIV, condomless anal sex [CAS], transactional sex or having a sexually transmitted infection [STI]) who could safely take PrEP were enrolled. Follow‐up visits were conducted at 4 weeks and then quarterly. We conducted logistic regression to identify factors associated with long‐term PrEP engagement (3+ follow‐up visits in 52 weeks) and complete self‐reported adherence (no missed pills in the past 30 days) during follow‐up. For both outcomes, we constructed multivariable models controlling for country, socio‐demographics, sexual behaviour, substance use, STIs and self‐reported adherence at 4 weeks (long‐term engagement outcome only). Results From March 2018 to June 2021, ImPrEP screened 519 TGW, enrolled 494 (Brazil: 190, Mexico: 66 and Peru: 238) and followed them for 52 weeks. At baseline, 27.5% of TGW were aged 18–24 years, 67.8% were mixed‐race and 31.6% had >secondary education. Most, 89.9% reported CAS, 61.9% had >10 sex partners and 71.9% reported transactional sex. HIV incidence was 1.82 cases per 100 person‐years (95% confidence interval [CI]: 0.76–4.38). Almost half of TGW (48.6%) had long‐term PrEP engagement, which was positively associated with reporting complete adherence at week 4 (aOR:2.94 [95%CI:1.88–4.63]) and was inversely associated with reporting CAS with unknown‐HIV partner (aOR:0.52 [95%CI:0.34–0.81]), migration (aOR:0.54 [95%CI:0.34–0.84]), and being from Mexico (aOR:0.28 [95%CI:0.14–0.53]). Self‐reported adherence was associated with TGW aged >34 (aOR:1.61 [95%CI:1.10–2.34]) compared to those aged 25–34 and those with >secondary education (aOR:1.55 [95%CI:1.10–2.19]) and was lower among TGW from Peru (aOR:0.29 [95%CI:0.21–0.41]) or reporting PrEP‐related adverse effects (aOR:0.63 [95%CI:0.42–0.92]). Conclusions Although TGW were willing to enrol in ImPrEP, long‐term PrEP engagement and complete self‐reported adherence were limited, and HIV incidence remained relatively high. A successful HIV prevention agenda should include trans‐specific interventions supporting oral PrEP and exploring long‐acting PrEP strategies for TGW.
Collapse
Affiliation(s)
- Kelika A. Konda
- Universidad Peruana Cayetano Heredia, Centro de Investigaciones Interdisciplinaria en Salud, Sexualidad, y SIDALimaPeru
| | - Thiago S. Torres
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI‐Fiocruz)Rio de JaneiroBrazil
| | - Gabriela Mariño
- Universidad Peruana Cayetano Heredia, Centro de Investigaciones Interdisciplinaria en Salud, Sexualidad, y SIDALimaPeru
| | - Alessandra Ramos
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI‐Fiocruz)Rio de JaneiroBrazil
| | - Ronaldo I. Moreira
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI‐Fiocruz)Rio de JaneiroBrazil
| | - Iuri C. Leite
- Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz (ENSP‐Fiocruz)Rio de JaneiroBrazil
| | - Marcelo Cunha
- Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz (ENSP‐Fiocruz)Rio de JaneiroBrazil
| | - Emilia M. Jalil
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI‐Fiocruz)Rio de JaneiroBrazil
| | - Brenda Hoagland
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI‐Fiocruz)Rio de JaneiroBrazil
| | - Juan V. Guanira
- Universidad Peruana Cayetano Heredia, Centro de Investigaciones Interdisciplinaria en Salud, Sexualidad, y SIDALimaPeru
| | - Marcos Benedetti
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI‐Fiocruz)Rio de JaneiroBrazil
| | | | | | | | - Hamid Vega‐Ramirez
- Instituto Nacional de Psiquiatria Ramon de la Fuente MuñizMexico CityMexico
| | - Valdilea G. Veloso
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI‐Fiocruz)Rio de JaneiroBrazil
| | - Carlos F. Caceres
- Universidad Peruana Cayetano Heredia, Centro de Investigaciones Interdisciplinaria en Salud, Sexualidad, y SIDALimaPeru
| | - Beatriz Grinsztejn
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI‐Fiocruz)Rio de JaneiroBrazil
| | | |
Collapse
|